Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Receivables (2016 - 2023)

Historic Change in Receivables for Spyre Therapeutics (SYRE) over the last 7 years, with Q4 2023 value amounting to -$163000.0.

  • Spyre Therapeutics' Change in Receivables rose 4455.78% to -$163000.0 in Q4 2023 from the same period last year, while for Sep 2024 it was -$163000.0, marking a year-over-year increase of 6778.66%. This contributed to the annual value of -$375000.0 for FY2023, which is 1477.27% up from last year.
  • Per Spyre Therapeutics' latest filing, its Change in Receivables stood at -$163000.0 for Q4 2023, which was up 4455.78% from -$1.5 million recorded in Q3 2023.
  • In the past 5 years, Spyre Therapeutics' Change in Receivables registered a high of $21.5 million during Q1 2021, and its lowest value of -$21.5 million during Q2 2021.
  • Moreover, its 3-year median value for Change in Receivables was -$45000.0 (2023), whereas its average is $0.0.
  • Data for Spyre Therapeutics' Change in Receivables shows a peak YoY increase of 34690.43% (in 2023) and a maximum YoY decrease of 88052.63% (in 2023) over the last 5 years.
  • Over the past 3 years, Spyre Therapeutics' Change in Receivables (Quarter) stood at $815000.0 in 2021, then tumbled by 136.07% to -$294000.0 in 2022, then skyrocketed by 44.56% to -$163000.0 in 2023.
  • Its Change in Receivables was -$163000.0 in Q4 2023, compared to -$1.5 million in Q3 2023 and $1.3 million in Q2 2023.